Oxolife

oxolife.com ↗ ·Barcelona ·Series A

Oxolife is a Barcelona-based clinical-stage biotech developing OXO-001, a non-hormonal oral pill that improves endometrial receptivity and embryo implantation to raise pregnancy and live-birth rates in IVF/ICSI patients. Founded in 2013 by Agnès Arbat and Ignasi Canals, it completed a Phase 2 trial (42.6% live birth rate vs 35.7% placebo, presented at ESHRE 2024) and is preparing a pivotal Phase 3 plus a secondary PCOS indication. CEO Agnès Arbat won the EU Women Innovators Prize at the 2025 EIC Summit; the company is currently fundraising and exploring pharma partnerships.

Founded

2013

Founders

Total funds raised

€5M

SectorsBiotech, Women's Health, Fertility, Pharmaceuticals, Healthtech Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Agnès Arbat

Co-founder, CEO & Chief Medical Officer

Ignasi Canals

Co-founder & Chief Scientific Officer

Global models 3

ObsEva

Switzerland · www.obseva.com ↗

Venture-backed clinical-stage biotech that developed nolasiban, an oral non-hormonal drug to improve embryo implantation and pregnancy rates in IVF, the closest match to OXO-001's model of licensing to pharma after late-stage trials.

$200MComparable

Gameto

United States · www.gameto.com ↗

Clinical-stage company building therapies to improve IVF outcomes, a VC-funded bet on regulated products for fertility clinics and patients.

$100MComparable

Freya Biosciences

Denmark · freyabiosciences.com ↗

Clinical-stage biotech developing drug candidates to improve implantation, pregnancy and live-birth rates in women struggling to conceive, including IVF patients.

$38MComparable